A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer (PAPGC)

Inclusion Criteria:

• Subjects voluntarily participated in the trial and signed the informed consent form;
• Aged ≥ 18 years and < 80 years, regardless of gender;
• Stable vital signs;
• Patients with gastric adenocarcinoma confirmed by gastroscopic biopsy;
• Tumors judged as unresectable by attending physicians;
• Receiving anti-PD-1 therapy combined with chemotherapy as first-line treatment;
• No history of allergic diseases and non-allergic constitution;
• No history of drug abuse;
• Non-pregnant and non-lactating females (applicable to male subjects as well);
• No participation in any drug clinical trial (including investigational drugs of this trial) within 3 months prior to enrollment.

Exclusion Criteria:

• Failure to meet the inclusion criteria, or individuals deemed inappropriate for trial participation by investigators;
• Concurrent primary malignant tumors at other sites;
• Poor general condition, severe infection, respiratory insufficiency, or other conditions leading to inability to cooperate with the trial;
• Patients with mental disorders, consciousness disturbance, or poor treatment compliance;
• Suspected or confirmed history of drug abuse;
• Immunodeficiency, or long-term use of immunosuppressants and glucocorticoids;
• Pregnant or lactating women;
• Sponsors, investigators directly involved in this trial, and their immediate family members;
• Individuals unsuitable for enrollment for any reason as judged by the investigator.